Motor-cognitive Performance in People With Multiple Sclerosis
Launched by KAROLINSKA INSTITUTET · Mar 12, 2024
Trial Information
Current as of July 23, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is studying a new balance training program designed specifically for people with multiple sclerosis (MS), called HiBalance-MS. The goal is to see if this program can help improve balance, walking, and overall quality of life for individuals with MS. Researchers believe that by participating in challenging balance exercises tailored to the needs of those with MS, participants may experience better control over their movements and daily activities.
To be eligible for this trial, participants must be between 18 and 65 years old, have a confirmed MS diagnosis, and be able to walk 100 meters without assistance. They should also have a certain level of disability from MS, as measured by a specific scale, and score below 25 on a balance test. People with significant cognitive issues or other conditions that affect balance may not qualify. Those who join the study can expect to engage in balance training sessions and contribute to important research that could lead to better support for others living with MS.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • an MS diagnosis according to McDonald criteria;
- • an overall MS-disability score from 2.0 to 5.5 according to the Expanded Disability Status Scale;
- • ability to walk 100 m without aid;
- • a maximum score of 24 in the Mini-BESTest (i.e., \< 25 points)
- • 18 to 65 years of age
- Exclusion Criteria:
- • cognitive impairment as indicated by a score \<21 in the Montreal Cognitive Assessment;
- • presence of other conditions that would substantially influence balance;
- • an MS relapse or change of disease-modifying treatment within the past 8 weeks
About Karolinska Institutet
Karolinska Institutet is a renowned medical university located in Sweden, recognized for its commitment to advancing healthcare through innovative research and education. As a leading sponsor of clinical trials, the institution focuses on translating scientific discoveries into effective treatments and therapies, emphasizing patient-centered approaches. With a strong emphasis on collaboration and interdisciplinary research, Karolinska Institutet plays a pivotal role in addressing global health challenges and improving patient outcomes, leveraging its extensive network of experts and state-of-the-art facilities to drive clinical advancements.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Stockholm, , Sweden
Patients applied
Trial Officials
Sverker Johansson, Ph.D
Principal Investigator
Karolinska Institutet, org.nr 202100-2973
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported